UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 22, 2009

ENDOCARE, INC.

(Exact name of registrant as specified in its charter)


Delaware	001-15063	33-0618093
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)

201 Technology Drive
Irvine, California 92618
(Address of Principal Executive Offices, including zip code)

(949) 450-5400
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

On June 22, 2009, we borrowed an additional $0.9 million under our credit facility with Silicon Valley Bank, bringing the total amount currently outstanding under the credit facility to $3.9 million.

The terms and conditions of the credit facility, as amended to date, are described in the Current Reports on Form 8-K that we filed on November 1, 2005, February 16, 2006, April 25, 2006, December 22, 2006, February 28, 2007, February 11, 2008, February 27, 2009 and May 27, 2009, which are hereby incorporated by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	ENDOCARE, INC.
June 26, 2009	By:	/s/ Michael R. Rodriguez
		Michael R. Rodriguez
		Senior Vice President, Finance and Chief Financial Officer

ENDOCARE INC 8-K